San Francisco based Attralus has raised US$ 25M in its Series A funding round on 14 September 2020. Attralus is a biopharmaceutical company focused on creating transformative medicines to improve the lives of patients.
The Series A funding round was led by venBio Partners. The funding will enable Attralus to further validate their pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain) and potentially ALECT2 systemic amyloidosis.
Systemic amyloidosis is a diverse group of approximately 30 disorders that occur due to protein misfolding. It produces amyloid fibrils that accumulate in multiple organs throughout the body. Deposited amyloid is toxic to organs and tissues and causes significant dysfunction. It can affect multiple major organs and tissues, including the heart, kidneys, liver, gastrointestinal tract and nerves. Most patients have less than five years of life expectancy from onset of symptoms like heart failure and kidney failure. Diagnosis of amyloidosis can be difficult and misdiagnosis can be deadly.
Attralus is researching for new breakthroughs for patients living with systemic amyloidosis. With the help of their novel, pan-amyloid targeting agents, they can visualize the pathology and progression of systemic amyloidosis by whole-body diagnostic imaging. They have partnered with Dr. Wall’s research group, which has more than 25 years of translational experience in amyloidosis.
About Attralus
Founded in 2019, Attralus is a biopharmaceutical which aims to improve the lives of patients suffering from systemic amyloidosis. The company’s proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. Its mission is to develop treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options. “We are excited to partner with the exceptional leaders at Attralus and develop transformative therapies for patients living with a range of systemic amyloid diseases,” said Dr. Richard Gaster, M.D., Ph.D., Partner at venBio.
